Qiagen N.V. (NASDAQ:QGEN) has been assigned an average rating of “Hold” from the fifteen analysts that are currently covering the firm, MarketBeat reports. Nine equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $32.56.

A number of equities research analysts have commented on QGEN shares. TheStreet cut shares of Qiagen N.V. from a “b-” rating to a “c” rating in a research note on Monday, April 24th. Commerzbank Ag restated a “buy” rating on shares of Qiagen N.V. in a research note on Monday, May 15th. Zacks Investment Research cut shares of Qiagen N.V. from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. BidaskClub upgraded shares of Qiagen N.V. from a “hold” rating to a “buy” rating in a research note on Wednesday, July 19th. Finally, Wells Fargo & Company restated a “market perform” rating and set a $31.00 target price (up previously from $28.00) on shares of Qiagen N.V. in a research note on Thursday, July 13th.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/18/qiagen-n-v-qgen-receives-average-recommendation-of-hold-from-analysts.html.

Several large investors have recently added to or reduced their stakes in the stock. Ngam Advisors L.P. bought a new stake in Qiagen N.V. during the first quarter valued at about $894,000. Prudential Financial Inc. bought a new stake in Qiagen N.V. during the first quarter valued at about $207,000. Edmond DE Rothschild Holding S.A. bought a new stake in Qiagen N.V. during the first quarter valued at about $46,480,000. Karp Capital Management Corp bought a new stake in Qiagen N.V. during the first quarter valued at about $5,862,000. Finally, BlackRock Inc. boosted its stake in Qiagen N.V. by 8,793.4% in the first quarter. BlackRock Inc. now owns 7,839,636 shares of the company’s stock valued at $227,114,000 after buying an additional 7,751,485 shares during the last quarter. Hedge funds and other institutional investors own 60.07% of the company’s stock.

Qiagen N.V. (NASDAQ QGEN) opened at 31.44 on Friday. Qiagen N.V. has a 52 week low of $24.86 and a 52 week high of $35.26. The company’s 50-day moving average is $33.06 and its 200 day moving average is $31.25. The stock has a market cap of $7.18 billion, a PE ratio of 96.15 and a beta of 1.14.

Qiagen N.V. (NASDAQ:QGEN) last released its earnings results on Thursday, July 27th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.02. Qiagen N.V. had a net margin of 5.44% and a return on equity of 11.04%. The company had revenue of $349 million for the quarter, compared to analysts’ expectations of $353.09 million. During the same quarter last year, the business earned $0.24 EPS. The firm’s revenue was up 4.4% compared to the same quarter last year. On average, analysts expect that Qiagen N.V. will post $1.23 earnings per share for the current fiscal year.

About Qiagen N.V.

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.